Agenda for the WAAW event "The rising tide of AMR – a high price to pay"
Friday, 18 November 2022
Lecture Theatre, Oxford Martin School, 34 Broad Street, OX1 3BD, Oxford
Pro-Vice Chancellor for Innovation and Professor of Translational Medicine, University of Oxford
Chas is Pro-Vice Chancellor for Innovation at the University of Oxford, Professor of Translational Medicine in the Nuffield Department of Clinical Medicine, Director of the Centre for Medicines Discovery, and Professorial Fellow at Keble College, Oxford. Prior to coming back to Oxford in 2008, Chas was Vice President and Head of Biology at GlaxoSmithKline. Chas is an invited expert on several government and charitable research funding bodies, and an advisor for many academic, biotech and pharma drug discovery programmes. In 2012 he was voted one of the “top innovators in the industry”, in 2014 received the “Rita and John Cornforth Award” from the Royal Society of Chemistry, in 2017 and 2018 was voted “Master of the Bench” from the Medicine Maker Power List, and in 2018 was awarded the “Order of the British Empire” in the New Years Honours List.
Sir Jim Ratcliffe was knighted in 2018 for services to business and investment. He is the founder and Chairman of INEOS. Sir Jim has funded the Ineos Oxford Institute with INEOS co-founders Andy Currie and John Reece. The trio have funded several initiatives in the public health space to date, including backing childrens running programmes GO Run for Fun and The Daily Mile, funding a new wing at the UK’s Defence and Military Rehabilitation Centre, funding a children’s A&E at Southampton Hospital and donating critical supplies of INEOS hand sanitizer to the front lines of the Covid-19 pandemic. The INEOS team see antimicrobial resistance as one of the biggest global threats in the near future and have provided funding to establish the IOI in order to support urgent scientific research in the field.
Assistant Director-General for the Antimicrobial Resistance Division, World Health Organization
Professor Hanan H. Balkhy is the first appointed Assistant Director-General for the Antimicrobial Resistance Division (AMR) at the World Health Organization (WHO), which is a flagship program for the World Health Organization with a mandate to lead the human health response to the emergence of antimicrobial resistance along with the relevant stakeholders. Dr Balkhy is a Professor of Paediatric Infection Diseases with over two decades of experience in the field of infectious diseases and Infection Prevention and Control (IPC), and as a clinician and a researcher. She has also led a WHO Collaborating Centre for IPC and AMR, established the Infectious Disease Research Unit at King Abdullah International Medical Research Centre and was the Editor-in-Chief of 5he Journal of Infection and Public Health for 10 years.
Founder and Senior Strategic Advisor, ReAct
Otto Cars is an MD and specialist in infectious diseases and a former head of the Department of Infectious Diseases at Uppsala University Hospital. In 2003, he was appointed Professor of Infectious Diseases and Antimicrobial Resistance at Uppsala University. Otto Cars was leading the Swedish strategic programme against antibiotic resistance on behalf of the Swedish government between 1995- 2010. He has served as an expert to the WHO and several European Agencies and was as a member of the UN Interagency Coordination Group on Antimicrobial Resistance (IACG). Otto Cars is the founder in 2005 of the international network Action on Antibiotic Resistance -ReAct ( www.reactgroup.org) which, supported by the Swedish International Development Cooperation Agency, is working on all continents as a catalyst, advocating for and supporting multilevel engagement on antibiotic resistance.
Senior Research Manager - Drug-Resistant Infections, Wellcome
Janet Midega is a Senior Research Manager for Wellcome’s Drug Resistant Infections (DRI) programme where she is providing scientific leadership, program development and management support to the surveillance and epidemiology program on Antimicrobial Resistance (AMR). At Wellcome, she led the recently published work on the burden of AMR and continues to lead science and policy research which aims at evaluating how legislative changes banning antibiotic use in animal meat production can reduce the potential transfer of resistant pathogens between animals and humans; and a surveillance program on the development of a comprehensive data capture system for patient-centred AMR surveillance in low- and middle-income countries. In line with the DRI programmes interest in accelerating the development of new antibiotics, Janet worked closely with CARB-x based at Boston University, USA in 2018/19, as part of Wellcome’s role as an accelerator and support for companies joining CARBx. Prior to joining Wellcome, Janet was a scientist at Imperial College and the University of Oxford, Big Data Institute; in collaboration with the KEMRI- Wellcome Trust Research Programme where she worked for over 15 years conducting academic research on the genomic epidemiology of malaria. Janet is also a Senior Fellow in Public Health at the Aspen Institute, Washington DC, USA.
Professor of Colorectal Surgery, University of Oxford, and President of the Royal College of Surgeons of England
Neil Mortensen is Emeritus Professor of Colorectal Surgery in the University of Oxford Medical School. He is Fellow of Green Templeton College. He trained in Birmingham, Bristol and St Mark’s Hospital and has clinical and research interests in a wide range of colorectal diseases. Neil was appointed President of the Royal College of Surgeons of England in early 2020 at the height of the pandemic.
Patient Support Lead, Antibiotic Research UK
Arlene is a Fellow of the Royal Pharmaceutical Society with over 25 years’ experience in pharmacy postgraduate education. As Assistant Director of NHS Education for Scotland (Pharmacy), she served as Education Lead within the Scottish Antimicrobial Prescribing Group. Arlene now works for Antibiotic Research UK, a charity fighting antibiotic resistance. In 2019 she set up and now leads the award-winning Patient Support Programme. Arlene provides information and support to patients throughout the UK suffering with resistant infection and is often invited to share that patient experience with policymakers, researchers and clinicians. Arlene is also Trustee of a Lyme disease charity.
The Lord O’Neill of Gatley
Lord O’Neill is a cross bench peer in the House of Lords. He is a member of the panel of Senior Advisors to Chatham House, Chair of Northern Gritstone and Vice Chair of the Northern Powerhouse Partnership. He is currently leading a Review into the growth of start-up businesses for the Shadow Chancellor. His previous roles include, joint head of research at Goldman Sachs (1995–2000), its chief economist (2001–10) and chairman of its asset management division (2010–13); creator of the acronym BRIC; chair of the City Growth Commission (2014); chair of the Review on Antimicrobial Resistance [AMR] (2014-16); commercial secretary to the Treasury (2015-16). He is a board member, and one of the founding trustees of educational charity SHINE. Lord O’Neill is an honorary professor of economics, University of Manchester, and holds honorary degrees from the University of Sheffield, University of Manchester, University of London and from City University London. He received his PhD from the University of Surrey and is now a Visiting Professor there.
Chair, Expert Advisory Group, Fleming Fund (Mott MacDonald, Management Agents)
Dr Catriona Waddington is chair of the Expert Advisory Group which advises on the work of the management agent for the Fleming Fund, Mott MacDonald. She is a health economist who has worked extensively with Ministries of Health in a number of countries, including Ethiopia, Ghana, Malawi and Tonga. Areas of professional focus include practical advice on prioritisation, the effects of out-of-pocket payments, and aid effectiveness (how donors can effectively work together and with governments in a country). She has been closely involved with the development of a costs-and-effects framework for AMR surveillance in low- and middle-income countries.
Head of Modelling and Evaluation for Healthcare Associated Infections and Antimicrobial Resistance, UK Health Security Agency
Working in the field for almost 20 years, Julie currently leads the AMR modelling and health economics group at UKHSA. She collaborates widely both nationally and internationally and is the AMR Research Lead for UKHSA and the Lead for Knowledge Mobilisation, with a keen interest in enabling research to generate impact. Julie is experienced in modelling to inform policy e.g. underpinning English MRSA screening strategies and primary care antibiotic prescribing reduction targets. She has >80 publications in the field and sits on multiple AMR scientific advisory committees. As a member of SPI-M-O, during the pandemic she helped provide evidence to SAGE on transmission and control of COVID-19.
Senior Researcher, Health Economics Research Centre, University of Oxford
Dr Laurence Roope is a Senior Researcher at the University of Oxford’s Health Economics Research Centre (HERC). His research lies broadly within health economics and development economics. He is especially interested in the economics of poverty and inequality, and in applying economic principles to tackle global challenges such as antimicrobial resistance, pandemics and climate change. His academic work has been published in a variety of prestigious economics and general interest scientific journals, including Science, Nature Medicine and PNAS. His research has also featured in multiple United Nations policy documents and he is regularly quoted in the media.
Managing Director | Head of Europe, Middle East and Africa Environmental, Social and Governance Research, Citi Research
Anita McBain is Head of ESG Research, EMEA and a Managing Director at Citi Research. She joined Citi from M&G Investments. Prior to M&G, Anita led research for an impact fund focused on mitigating climate change and tackling deforestation. Earlier in her career, Anita worked for various investment firms and global banks as a fixed income analyst. Anita holds a Master’s Degree from the University of Cambridge, an MBA from the University of Edinburgh, and a BSc in Computer Systems from City University London. Anita most recently submitted her Master’s thesis on the integration of biodiversity loss into the investment process.
Director, Oxford Martin School
Professor Charles Godfray was appointed Director of the Oxford Martin School on 1 February 2018. He is a population biologist with broad interests in the environmental sciences and has published in fundamental and applied areas of ecology, evolution and epidemiology. He is interested in how the global food system will need to change and adapt to the challenges facing humanity in the 21st century, and in particular in the concept of sustainable intensification, and the relationship between food production, ecosystem services and biodiversity. In 2017 he was knighted for services to scientific research and for scientific advice to government.
Agenda for the WAAW event "The rising tide of AMR – a high price to pay"
Learn more about antimicrobial resistance (AMR)
Our mission is to rapidly advance research, education and collaboration in search of solutions to tackle AMR